| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01381640 Details | 2016-07-06 Interventional | 1 | 0 | Acetaminophen Healthy Subject… | Study was cancelled prior to enrolling any subjects. - | |||
| NCT00951444 Details | 2016-07-06 Interventional | 2 | 0 | Carboplatin Gemcitabine Lung Neoplasms Lung Cancer | The study was not activated. - | |||
| NCT00571740 Details | 2016-07-06 Interventional | 2 | 0 | Bevacizumab Calcium Cetuximab Fluorouracil Leucovorin Levoleucovorin Oxaliplatin Colorectal Neop… Colorectal Canc… | The study was not activated - | |||
| NCT00268437 Details | 2016-07-06 Interventional | 2 | [2 Refs] | 27 | Carboplatin Pemetrexed Esophageal Neop… Esophageal Canc… | Trial closed early because, during an interim analysis, the primary endpoint fell short. - | ||
| NCT01798485 2012-004349-34 Details | 2016-07-01 Interventional | 3 | 696 | Docetaxel Adenocarcinoma Adenocarcinoma … Carcinoma, Non-… Lung Neoplasms Non-Small-Cell … Non-small Cell … Non-small Cell … Non-small Cell … | The study was stopped after the first Interim Analysis due to futility. - | |||
| NCT01003938 Details | 2016-06-30 Interventional | 2 | 6 | Erlotinib Hydro… Topotecan Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | due to administrative issue and financial sponsor decision to suspend ovarian cancer studies - | |||
| NCT01473303 Details | 2016-06-28 Interventional | 1/2 | 0 | Calcium Fluorouracil Irinotecan Leucovorin Levoleucovorin Oxaliplatin Pancreatic Neop… Pancreatic Canc… | CALGB 81003 closed about a week after it was activated because of withdrawal of support. No
patients were registered on this study. - | |||
| NCT01092832 2009-012848-16 Details | 2016-06-23 Interventional | 3 | 23 | Voriconazole Candidiasis | This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any
safety issues or concerns. The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design. | |||
| NCT01808950 Details | 2016-06-22 Interventional | 1/2 | 4 | Resiquimod Carcinoma Carcinoma, Basa… Nodular Basal C… | safety issues - | |||
| NCT00532311 Details | 2016-06-22 Interventional | 3 | 411 | Atorvastatin Dihydromevinoli… Hydroxymethylgl… L 647318 Lovastatin Pravastatin Rosuvastatin Ca… Simvastatin Hypercholestero… | Overall profile of the compound does not offer significant clinical advantage to patients over
currently available lipid lowering agents - | |||
| NCT02786979 Details | 2016-06-21 Interventional | 4 | 190 | Aspirin Beraprost Arteriosclerosi… Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy. - | |||
| NCT01048086 Details | 2016-06-21 Interventional | 2 | 0 | Isotretinoin Tretinoin Neuroblastoma Neuroendocrine … Neuroendocrine … | No patients were enrolled because the company that pledged the drug does not yet have it
available. - | |||
| NCT02177734 2014-000796-27 Details | 2016-06-20 Interventional | 1 | 0 | Vaccines Influenza, Huma… Influenza | The study was cancelled for scientifically legitimate reasons not related to safety or efficacy
of the vaccine. - | |||
| NCT01428154 Details | 2016-06-17 Interventional | 1 | 0 | Darbepoetin alf… Anemia Kidney Diseases Renal Insuffici… Chronic Kidney … | Difficulty in recruitment. PDCO in the Day 30 summary report agrred to remove the PK study in
children <1 year of age. - | |||
| NCT01373918 Details | 2016-06-16 Interventional | 4 | 41 | Soybean oil, ph… Cholestasis Digestive Syste… Gastrointestina… | The study was terminated due to slow enrollment. Early termination leading to small number of subjects analyzed. | |||
| NCT00831649 Details | 2016-06-16 Interventional | 2 | - | Natalizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | The biological effect seen with natalizumab was not sufficient to warrant further development
in RA. - | |||
| NCT00801125 Details | 2016-06-16 Interventional | 4 | 0 | Natalizumab Crohn Disease Crohn's Disease | Study sponsor decided to withdraw the current study prior to enrollment of first participant. - | |||
| NCT00751296 Details | 2016-06-16 Interventional | 2 | 27 | Lenalidomide Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Seven years of follow-up & final analysis done in Dec 2012. Original study protocol used a starting lenalidomide dose of 10mg OD for 21days of a 28-day cycle, escalating weekly by 5mg to a target of 25mg daily. Toxicities reported with the first two enrolled patients lead to the current protocol amendment. | |||
| NCT02378740 Details | 2016-06-15 Interventional | 4 | 0 | Ketamine Anesthesia Pain Surgery | PI has left the University - | |||
| NCT02087176 Details | 2016-06-14 Interventional | 2 | 48 | Adavosertib Antimitotic Age… Carcinoma, Non-… Lung Neoplasms Previously Trea… | The study was terminated early by the sponsor. The sponsor terminated the study early. The study was closed on May 12, 2015. Part B of the study was not done. |